Tech Company Financing Transactions
Micreos Funding Round
On 10/25/2022, Micreos announced $25 million in financing from private investors.
Transaction Overview
Company Name
Announced On
10/25/2022
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Bankaplein 2
The Hague, 2585 EV
The Netherlands
The Hague, 2585 EV
The Netherlands
Phone
Website
Email Address
Overview
Micreos develops the world's first targeted antibacterial products, set to replace antibiotics. The company is viewed as global leader spearheading this exciting new field. With Micreos endolysin technology, for the first time we can kill only the unwanted bacteria - including antibiotic resistant strains - while preserving the beneficial bacteria, essential for our health.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mark Offerhaus
Chief Financial Officer
Joost Goderie
Chief Medical Officer
Johan Frieling
Chief Operating Officer
Michael Riedlin
Chief Scientific Officer
Fritz Eichenseher
Chief Scientific Officer
Steven Hagens
VP - Bus. Development
Fred Berendsen
VP - Bus. Development
Josephine Offerhaus
VP - Bus. Development
Floor Pietersma
VP - General Counsel
Michiel van den Bosch
Browse more venture capital transactions:
Prev: 10/25/2022: Sealance venture capital transaction
Next: 10/25/2022: Resonai venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs